LBO-02-Elafibranor, a peroxisome proliferator-activted receptor alpha and delta agonist demonstrates favourable efficacy and safety in patients with primary biliary cholangitis and inadequate response to ursodeoxycholic acid treatment
暂无分享,去创建一个
D. Magrez | K. Kowdley | V. Luketic | M. Heneghan | G. Hirschfield | D. Jones | S. Caldwell | A. Bonder | C. Levy | A. Parés | D. Pratt | J. Vierling | M. Bchir | Rémy Hanf | P. Birman | S. Megnien | Pd Dr. Schattenberg Jörn | S. Megnien